










Does Nrf2 help nerves to survive?
Dimethyl fumarate (DMF) has recently been
approved for the treatment of relapsing-remitting
multiple sclerosis (RRMS) after showing beneficial
effects on clinical and radiologic endpoints in 2 phase
3 clinical trials.1,2 While DMF’s mode of action is not
completely understood, experimental data suggest
that putative neuroprotective properties may be
mediated by the nuclear factor (erythroid-derived
2)-like 2 (Nrf2) pathway.3,4 Specifically, DMF leads
to translocation of Nrf2 to the nucleus, thereby
enhancing the expression of antioxidant enzymes
and promoting neuroprotection in cell culture mod-
els.4 In line with this, DMF improved the clinical
course and preservation of myelin, axons, and neu-
rons in an animal model of MS. These effects were
lost in Nrf2-deficient mice, suggesting a central role
for Nrf2 in mediating neuroprotection.3
In this issue of Neurology® Neuroimmunology &
Neuroinflammation, Metz et al.5 report on a patient
with RRMS who after more than 1 year of DMF
treatment underwent brain biopsy for a large unusual
left occipital lesion. Histopathologic workup of this
lesion revealed a more than 6-fold higher number of
Nrf2-positive nuclei than control lesions from
patients with MS not treated with DMF. The most
prominent nuclear Nrf2 signal was observed in astro-
cytes, whereas other cell types such as oligodendro-
cytes and lymphocytes displayed a predominantly
cytoplasmic staining. Metz et al. could also analyze
biopsied lesions from 3 patients with psoriasis who
had developed progressive multifocal leukoencepha-
lopathy (PML) as a rare complication of ongoing
fumarate treatment. Lesions from 2 of those 3 pa-
tients likewise exhibited higher numbers of Nrf2-
positive nuclei than control PML lesions.
Although based on only a few cases, these data
provide circumstantial evidence that DMF treat-
ment may induce nuclear translocation of Nrf2 in
CNS cells in vivo, thus potentially preventing oxida-
tive damage of neurons and glial cells in vivo.
Nevertheless, the findings of Metz et al. are derived
from single biopsies and therefore do not permit us
to draw conclusions on the temporal dynamics of
Nrf2 expression. Another note of caution is that
the MS lesion was biopsied 8 weeks after the last
DMF dosage, raising the question as to whether
levels of DMF would have been sufficiently high
to exert biological functions at that time. Although
the results of Metz et al. therefore do not formally
prove Nrf2 nuclear translocation in patients treated
with fumarate, they are consistent with previous ob-
servations in cell culture experiments and allow for
the possibility that a similar mechanism may operate
in vivo.
Do these intriguing findings indicate that Nrf2
helps nerves to survive? Findings from the experimen-
tal autoimmune encephalomyelitis model indeed
suggest that DMF treatment may be associated with
an ameliorated disease course, in particular in the late
stages of the disease.3 However, answering the ques-
tion of whether DMF’s interesting effects in cell
culture and animal models translate into measurable
and clinically meaningful neuroprotective effects in
patients will require carefully designed long-term
studies with appropriate endpoints. In this regard, 2
recent phase 3 trials of DMF for RRMS have evalu-
ated the effects of DMF treatment on the reduction of
brain atrophy, an MRI surrogate measure of neuro-
protection.6,7 In the DEFINE study, relative reduc-
tions in brain atrophy over a 2-year period were
statistically significant only for DMF twice daily but
not 3 times daily.6 In the CONFIRM study, reduc-
tions in brain atrophy with DMF compared with
placebo did not reach statistical significance over a
2-year period.7 Thus, these studies do not yet seem
to provide definitive evidence for neuroprotective
effects of DMF, at least as measured by the reduction
of brain atrophy on MRI. MRI studies with a longer
follow-up appear to be warranted to further analyze
those effects. Finally, and perhaps most importantly,
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the ultimate measure of neuroprotective properties of
any disease-modifying therapy for MS will be the
demonstration of beneficial effects on the patients’
overall level of functioning, including cognitive and
motor capacities, in the long term.
NOTE ADDED IN TEXT
DMF’s safety profile is generally considered favorable; however, a recent
case of PML underscores the necessity for further pharmacovigilance.8
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